Maria K Magnusson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6648767/publications.pdf

Version: 2024-02-01

49 papers	1,548 citations	304602 22 h-index	315616 38 g-index
50 all docs	50 docs citations	50 times ranked	2549 citing authors

#	Article	IF	Citations
1	MEFV and NLRP3 Inflammasome Expression Is Attributed to Immature Macrophages and Correlates with Serum Inflammatory Proteins in CrohnÂ´s Disease Patients. Inflammation, 2022, 45, 1631-1650.	1.7	4
2	Fecal luminal factors from patients with irritable bowel syndrome induce distinct gene expression of colonoids. Neurogastroenterology and Motility, 2022, 34, e14390.	1.6	4
3	TREM-1+ Macrophages Define a Pathogenic Cell Subset in the Intestine of Crohnâ€™s Disease Patients. Journal of Crohn's and Colitis, 2021, 15, 1346-1361.	0.6	10
4	Impaired Butyrate Induced Regulation of T Cell Surface Expression of CTLA-4 in Patients with Ulcerative Colitis. International Journal of Molecular Sciences, 2021, 22, 3084.	1.8	6
5	Fecal microbiota dynamics during disease activity and remission in newly diagnosed and established ulcerative colitis. Scientific Reports, 2021, 11, 8641.	1.6	9
6	A Distinct Faecal Microbiota and Metabolite Profile Linked to Bowel Habits in Patients with Irritable Bowel Syndrome. Cells, 2021, 10, 1459.	1.8	23
7	Impaired Luminal Control of Intestinal Macrophage Maturation in Patients With Ulcerative Colitis During Remission. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 1415-1432.	2.3	9
8	Aloe barbadensis Mill. extract improves symptoms in IBS patients with diarrhoea: post hoc analysis of two randomized double-blind controlled studies. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110481.	1.4	4
9	The Effects of Human Milk Oligosaccharides on Gut Microbiota, Metabolite Profiles and Host Mucosal Response in Patients with Irritable Bowel Syndrome. Nutrients, 2021, 13, 3836.	1.7	17
10	Systemic Inflammatory Protein Profiles Distinguish Irritable Bowel Syndrome (IBS) and Ulcerative Colitis, Irrespective of Inflammation or IBS-Like Symptoms. Inflammatory Bowel Diseases, 2020, 26, 874-884.	0.9	24
11	The Anti-inflammatory Immune Regulation Induced by Butyrate Is Impaired in Inflamed Intestinal Mucosa from Patients with Ulcerative Colitis. Inflammation, 2020, 43, 507-517.	1.7	38
12	Fecal microbiota composition is linked to the postoperative disease course in patients with Crohnâ€™s disease. BMC Gastroenterology, 2020, 20, 130.	0.8	15
13	Human milk oligosaccharide supplementation in irritable bowel syndrome patients: A parallel, randomized, doubleâ€blind, placeboâ€controlled study. Neurogastroenterology and Motility, 2020, 32, e13920.	1.6	32
14	Randomized clinical trial: Effects of Aloe barbadensis Mill. extract on symptoms, fecal microbiota and fecal metabolite profiles in patients with irritable bowel syndrome. Neurogastroenterology and Motility, 2020, 32, e13860.	1.6	10
15	The frequency of circulating integrin Î±4Î²7⁺ cells correlates with protection against Helicobacter pylori infection in immunized mice. Helicobacter, 2019, 24, e12658.	1.6	4
16	Mucosal and Systemic Immune Profiles Differ During Early and Late Phases of the Disease in Patients With Active Ulcerative Colitis. Journal of Crohn's and Colitis, 2019, 13, 1450-1458.	0.6	16
17	A distinct gut microbiota composition in patients with ankylosing spondylitis is associated with increased levels of fecal calprotectin. Arthritis Research and Therapy, 2019, 21, 248.	1.6	59
18	Osteoporosis and skeletal dysplasia caused by pathogenic variants in SGMS2. JCI Insight, 2019, 4, .	2.3	47

#	Article	IF	Citations
19	Activated T follicular helper-like cells are released into blood after oral vaccination and correlate with vaccine specific mucosal B-cell memory. Scientific Reports, 2018, 8, 2729.	1.6	51
20	Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Scandinavian Journal of Gastroenterology, 2018, 53, 379-389.	0.6	134
21	Faecal secretogranin and chromogranin levels persist over time and are unrelated to disease history and outcome in patients with ulcerative colitis. Cogent Medicine, 2018, 5, 1484602.	0.7	2
22	Altered intestinal antibacterial gene expression response profile in irritable bowel syndrome is linked to bacterial composition and immune activation. Neurogastroenterology and Motility, 2018, 30, e13468.	1.6	15
23	Effects of Anti-TNFÎ±Treatment on Mucosal Expression of IL-17A, IL-21, and IL-22 and Cytokine-Producing T Cell Subsets in Crohnâ€™s Disease. Mediators of Inflammation, 2018, 2018, 1-7.	1.4	2
24	The Mucosal Antibacterial Response Profile and Fecal Microbiota Composition Are Linked to the Disease Course in Patients with Newly Diagnosed Ulcerative Colitis. Inflammatory Bowel Diseases, 2017, 23, 956-966.	0.9	17
25	Mucosal immune system of the gastrointestinal tract: maintaining balance between the good and the bad. Scandinavian Journal of Gastroenterology, 2017, 52, 1185-1193.	0.6	146
26	Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition. Journal of Crohn's and Colitis, 2016, 10, 943-952.	0.6	127
27	An Antibody Against Triggering Receptor Expressed on Myeloid Cells 1 (TREM-1) Dampens Proinflammatory Cytokine Secretion by Lamina Propria Cells from Patients with IBD. Inflammatory Bowel Diseases, 2016, 22, 1803-1811.	0.9	20
28	Effects of Aloe barbadensis Mill. extract (AVH200Â®) on human blood T cell activity in vitro. Journal of Ethnopharmacology, 2016, 179, 301-309.	2.0	20
29	Reduced numbers of mucosal DR^{int}macrophages and increased numbers of CD103⁺dendritic cells during anti-TNF-Î± treatment in patients with Crohnâ€™s disease. Scandinavian Journal of Gastroenterology, 2016, 51, 692-699.	0.6	25
30	Cultured blood Tâ€cell responses predict antiâ€<scp>TNF</scp> therapy response in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2015, 41, 1149-1161.	1.9	10
31	Response to Infliximab Therapy in Ulcerative Colitis is Associated With Decreased Monocyte Activation, Reduced CCL2 Expression and Downregulation of Tenascin C. Journal of Crohn's and Colitis, 2015, 9, 56-65.	0.6	35
32	Global mucosal and serum cytokine profile in patients with ulcerative colitis undergoing anti-TNF therapy. Scandinavian Journal of Gastroenterology, 2015, 50, 1118-1126.	0.6	38
33	Spontaneous Colitis in Muc2-Deficient Mice Reflects Clinical and Cellular Features of Active Ulcerative Colitis. PLoS ONE, 2014, 9, e100217.	1.1	93
34	Health Equilibrium Initiative: a public health intervention to narrow the health gap and promote a healthy weight in Swedish children. BMC Public Health, 2014, 14, 763.	1.2	2
35	CD25 and TNF receptor II reflect early primary response to infliximab therapy in patients with ulcerative colitis. United European Gastroenterology Journal, 2013, 1, 467-476.	1.6	10
36	Toxic activity of the CdtB component of Haemophilus ducreyi cytolethal distending toxin expressed from an adenovirus 5 vector. Apmis, 2010, 118, 143-149.	0.9	4

#	Article	IF	Citations
37	Adenovirus 5â€“Fiber 35 Chimeric Vector Mediates Efficient Apical Correction of the Cystic Fibrosis Transmembrane Conductance Regulator Defect in Cystic Fibrosis Primary Airway Epithelia. Human Gene Therapy, 2010, 21, 251-269.	1.4	20
38	Clinical Adenoviral Gene Therapy for Prostate Cancer. Human Gene Therapy, 2010, 21, 807-813.	1.4	25
39	Adenovirus-Derived Vectors for Prostate Cancer Gene Therapy. Human Gene Therapy, 2010, 21, 795-805.	1.4	29
40	A lentiviral vectorâ€based adenovirus fiberâ€pseudotyping approach for expedited functional assessment of candidate retargeted fibers. Journal of Gene Medicine, 2009, 11, 990-1004.	1.4	9
41	Novel strategies in tailoring human adenoviruses into therapeutic cancer geneÂtherapy vectors. Future Virology, 2008, 3, 45-59.	0.9	4
42	Protein Crystals in Adenovirus Type 5-Infected Cells: Requirements for Intranuclear Crystallogenesis, Structural and Functional Analysis. PLoS ONE, 2008, 3, e2894.	1.1	32
43	An Oncolytic Adenovirus Redirected with a Tumor-Specific T-Cell Receptor. Cancer Research, 2007, 67, 11309-11316.	0.4	22
44	Adenovirus type 5 fiber knob domain has a critical role in fiber protein synthesis and encapsidation. Journal of General Virology, 2006, 87, 3151-3160.	1.3	27
45	Gene Transduction and Cell Entry Pathway of Fiber-Modified Adenovirus Type 5 Vectors Carrying Novel Endocytic Peptide Ligands Selected on Human Tracheal Glandular Cells. Journal of Virology, 2004, 78, 7227-7247.	1.5	34
46	The Maturation of Murine Dendritic Cells Induced by Human Adenovirus Is Mediated by the Fiber Knob Domain. Journal of Biological Chemistry, 2003, 278, 37175-37182.	1.6	52
47	Adenovirus stripping: a versatile method to generate adenovirus vectors with new cell target specificity. Molecular Therapy, 2003, 7, 692-699.	3.7	32
48	Genetic retargeting of adenovirus vectors: functionality of targeting ligands and their influence on virus viability. Journal of Gene Medicine, 2002, 4, 356-370.	1.4	73
49	Genetic Retargeting of Adenovirus: Novel Strategy Employing â€œDeknobbingâ€•of the Fiber. Journal of Virology, 2001, 75, 7280-7289.	1.5	107